Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in LKFT held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 16.7M | $500.2M | 0.0% | 25.514% | 30.34% |
| 2 | TANG CAPITAL MANAGEMENT LLC | 3.8M | $113.5M | 0.0% | 5.781% | 5.16% |
| 3 | Madison Avenue Partners, LP | 3.4M | $103.4M | +39.9% | 5.265% | 4.45% |
| 4 | Prosight Management, LP | 2.0M | $61.3M | +31.8% | 3.120% | 10.56% |
| 5 | EcoR1 Capital, LLC | 1.7M | $50.0M | 0.0% | 2.546% | 2.43% |
| 6 | AMERIPRISE FINANCIAL INC | 1.3M | $38.1M | -10.7% | 1.943% | 0.01% |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 601K | $18.0M | +29.9% | 0.918% | 0.00% |
| 8 | DME Capital Management, LP | 483K | $14.5M | 0.0% | 0.737% | 0.37% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 408K | $12.2M | +29.3% | 0.623% | 0.02% |
| 10 | BlackRock, Inc. | 338K | $10.1M | +8.3% | 0.516% | 0.00% |
| 11 | Point72 Asset Management, L.P. | 270K | $8.1M | -18.8% | 0.412% | 0.01% |
| 12 | D. E. Shaw & Co., Inc. | 198K | $5.9M | -8.3% | 0.302% | 0.00% |
| 13 | MILLENNIUM MANAGEMENT LLC | 181K | $5.4M | +67.8% | 0.277% | 0.00% |
| 14 | UBS Group AG | 168K | $5.0M | -4.1% | 0.257% | 0.00% |
| 15 | DAFNA Capital Management LLC | 130K | $3.9M | 0.0% | 0.199% | 0.74% |
| 16 | CITADEL ADVISORS LLC | 88K | $2.6M | -39.8% | 0.135% | 0.00% |
| 17 | TWO SIGMA INVESTMENTS, LP | 82K | $2.5M | +216.1% | 0.125% | 0.00% |
| 18 | NORGES BANK | 77K | $2.3M | — | 0.117% | 0.00% |
| 19 | ALPS ADVISORS INC | 66K | $2.0M | +22.1% | 0.100% | 0.01% |
| 20 | GOLDMAN SACHS GROUP INC | 57K | $1.7M | +24.7% | 0.086% | 0.00% |
| 21 | AMERICAN CENTURY COMPANIES INC | 41K | $1.2M | +5.2% | 0.062% | 0.00% |
| 22 | BAROMETER CAPITAL MANAGEMENT INC. | 41K | $1.2M | +7.1% | 0.062% | 0.34% |
| 23 | MORGAN STANLEY | 38K | $1.1M | +41.6% | 0.057% | 0.00% |
| 24 | Schonfeld Strategic Advisors LLC | 33K | $977K | — | 0.050% | 0.00% |
| 25 | MARSHALL WACE, LLP | 32K | $971K | — | 0.050% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in LKFT — a direct measure of their conviction.
Filings activity in LKFT during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new LKFT position in Q2 2026
Institutions that fully closed their LKFT position in Q2 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | 12% | 49.64% | +1.18 pp | $973M | +2.5% |
| Q1 2026 | 90 | 1.1% | 48.46% | +0.79 pp | $949M | 7.9% |
| Q4 2025 | 91 | 2.2% | 47.67% | 0.14 pp | $1.03B | 5.5% |
| Q3 2025 | 93 | +9.4% | 47.81% | +0.14 pp | $1.09B | +24% |
| Q2 2025 | 85 | +1.2% | 47.67% | +0.18 pp | $878M | +12% |
| Q1 2025 | 84 | +3.7% | 47.49% | +0.39 pp | $785M | 8.2% |
| Q4 2024 | 81 | +3.8% | 47.10% | +26.64 pp | $854M | +121% |
| Q3 2024 | 78 | — | 20.46% | — | $387M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying LKFT stock.
Based on Q2 2026 13F filings, institutional ownership of Lakefront Biotherapeutics N.V. stands at 49.6%, held across 79 reporting institutions.
GILEAD SCIENCES, INC. is the largest reported institutional holder of LKFT, with approximately 16,707,477 shares worth $0.50B as of Q2 2026.
Yes — 6 widely-followed marquee investors appear among the top 25 institutional holders of LKFT, including SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for LKFT is 67 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
9 institutions opened new positions in LKFT during Q2 2026, while 21 fully exited. 27 added to existing positions and 35 trimmed.
LKFT institutional ownership rose by 1.18 percentage points quarter-over-quarter, with a net change of -11 holders.
The top 10 institutions account for 94.7% of all reported 13F value in LKFT, and the top 25 account for 99.3%.
Across the largest Immunology Biotech peers, institutional ownership levels are: YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.